ALS

ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX

Retrieved on: 
Friday, February 16, 2024

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors

Retrieved on: 
Friday, February 16, 2024

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ) securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ) securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • Amylyx investors have until April 9, 2024 to file a lead plaintiff motion.
  • Investors suffering losses on their Amylyx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

Retrieved on: 
Friday, February 16, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.
  • “Rich and Karen strengthen our commercial and clinical bench, better positioning us to capitalize on this exciting period in the life sciences industry,” said Todd Davis, CEO of Ligand.
  • “These appointments are the latest in Ligand’s initiative to enhance and scale our deal capabilities by selectively adding new talent.
  • He also served as co-head of the healthcare team at Hayfin Capital Management LLP, which deployed $1.4 billion in capital over four years.

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 15, 2024

Our strong 2023 commercial results reflect that physicians are more regularly screening for hypercortisolism.

Key Points: 
  • Our strong 2023 commercial results reflect that physicians are more regularly screening for hypercortisolism.
  • Corcept’s fourth quarter 2023 revenue was $135.4 million, compared to $103.1 million in the fourth quarter of 2022.
  • Diluted net income per common share was $0.28 in the fourth quarter of 2023, compared to $0.14 in the fourth quarter of 2022.
  • Cash and investments were $425.4 million at December 31, 2023 compared to $436.6 million at December 31, 2022.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors

Retrieved on: 
Thursday, February 15, 2024

Amylyx investors have until April 9, 2024 to file a lead plaintiff motion.

Key Points: 
  • Amylyx investors have until April 9, 2024 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.
  • On this news, Amylyx’s stock price fell $5.74, or 31.9%, to close at $12.26 per share on November 9, 2023, thereby injuring investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors

Retrieved on: 
Thursday, February 15, 2024

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ) securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ) securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • Amylyx investors have until April 9, 2024 to file a lead plaintiff motion.
  • On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.
  • On this news, Amylyx’s stock price fell $5.74, or 31.9%, to close at $12.26 per share on November 9, 2023, thereby injuring investors.

OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union

Retrieved on: 
Thursday, February 15, 2024

GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has received Orphan Drug Designation (ODD) in the European Union (EU) for the treatment of amyotrophic lateral sclerosis (ALS).

Key Points: 
  • GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has received Orphan Drug Designation (ODD) in the European Union (EU) for the treatment of amyotrophic lateral sclerosis (ALS).
  • AIT-101 previously received ODD from the U.S. FDA in June 2023 for the treatment of ALS.
  • “OrphAI Therapeutics now has orphan designation for AIT-101 both in the US and the EU for the treatment of ALS, an important step toward bringing the drug to patients suffering from this neurodegenerative disorder,” said Dr. Brigette Roberts, CEO and Director of OrphAI.
  • “AIT-101 has demonstrated compelling activity in its ability to clear toxic aggregates, which are a hallmark of ALS and other neurodegenerative diseases.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of Investors

Retrieved on: 
Thursday, February 15, 2024

Law Offices of Howard G. Smith announces an investigation on behalf of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ) investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ) investors concerning the Company’s possible violations of federal securities laws.
  • On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.
  • On this news, Amylyx’s stock price fell $5.74, or 31.9%, to close at $12.26 per share on November 9, 2023, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

FIRST LOOK FOR CHARITY FUNDRAISER AT THE 2024 CHICAGO AUTO SHOW RAISES $2.8 MILLION FOR LOCAL CHARITIES

Retrieved on: 
Thursday, February 15, 2024

CHICAGO, Feb. 15, 2024 /PRNewswire/ -- The Chicago Auto Show raised more than $2.8 million benefiting 18 local charities at the First Look for Charity gala.

Key Points: 
  • CHICAGO, Feb. 15, 2024 /PRNewswire/ -- The Chicago Auto Show raised more than $2.8 million benefiting 18 local charities at the First Look for Charity gala.
  • The Chicago Auto Show raised more than $2.8 million benefiting 18 local charities at the First Look for Charity gala.
  • First Look for Charity provides attendees with an exclusive viewing of the Chicago Auto Show a day before it opens to the public.
  • The 2024 Chicago Auto Show runs from Feb. 10-19, opening daily at 10 a.m. For more information, please visit FirstLookforCharity.org .

Brooke Eby, ALS Patient and Advocate, to deliver Keynote Address at 2024 MDA Clinical & Scientific Conference

Retrieved on: 
Thursday, February 15, 2024

New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific Conference (being held in Orlando, FL March 3-6), where she will address the world’s leaders in neuromuscular disease research and care.

Key Points: 
  • New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific Conference (being held in Orlando, FL March 3-6), where she will address the world’s leaders in neuromuscular disease research and care.
  • As the largest US gathering focused solely on neuromuscular diseases including ALS, the 2024 MDA Clinical & Scientific Conference promises to delve into the latest research advancements and clinical achievements in the field.
  • "We are honored to have Brooke Eby grace our conference to share her story and insights as a patient and as a patient advocate," remarked Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.
  • Members of the neuromuscular community who are registered with MDA are welcome to participate in the virtual conference at no-cost.